Barclays analyst Luke Sergott raised the firm’s price target on Danaher to $290 from $277 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher Reports Fourth Quarter and Full Year 2022 Results
- Early notable gainers among liquid option names on January 10th
- Danaher CEO to Comment on Financial Performance
- Danaher sees Q4 revenue up low-single digits, consensus 7.71B